GRAdHIVNE1 Vaccine

Phase 1Vaccine

IInternational AIDS Vaccine Initiative

GRAdHIVNE1 Vaccine is one of 3 small molecule programs targeting Adenovirus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenovirusRecruiting

AdenovirusPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Adenovirus

#DrugCompanyPhaseTrials

Adenovirus Specific T- Lymphocytes

JJessie L. Alexander

Phase 2

1 2

Cytomegalovirus Specific T-Lymphocytes

JJessie L. Alexander

Phase 2

1 3

GRAdHIVNE1 Vaccine

IInternational AIDS Vaccine Initiative

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Adenovirus

NCT06617091

Clinical

Trials by Indication[1]

Adenovirus1 trial

A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and With HIV.

Recruiting·IInternational AIDS Vaccine Initiative·Phase 1·NCT06617091·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GRAdHIVNE1 Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GRAdHIVNE1 Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GRAdHIVNE1 Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — International AIDS Vaccine Initiative company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: IInternational AIDS Vaccine Initiative

GRAdHIVNE1 Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Adenovirus1 trial

References

Drug Info

Quick Facts

Related News